Results 211 to 220 of about 683,828 (283)

TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma

open access: yesHistopathology, Volume 89, Issue 5, Page 779-785, November 2026.
Frequently positive TROP2 IHC suggests that TROP2 antibody‐drug conjugates may be potential treatments for LCNEC. Introduction TROP2 antibody‐drug conjugates have shown promising anti‐tumour activity, but neither the activity of these agents nor TROP2 expression has been well studied in pulmonary large cell neuroendocrine carcinoma (LCNEC), a rare and ...
Michael Minkley   +6 more
wiley   +1 more source

A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity. [PDF]

open access: yesAngew Chem Int Ed Engl, 2014
Richichi B   +7 more
europepmc   +1 more source

The Leukocyte Landscape Across Mouse Strains and Tissues

open access: yesImmunology &Cell Biology, Volume 104, Issue 10, Page 1019-1034, November‐December 2026.
The blood, bone marrow, liver, lymph nodes, and spleen of naïve male mice contained unique immunobiomes which differed between commonly used strains. BALB‐derived strains exhibited helper‐ and innate‐biased immune profiles, C57BL/6J‐derived strains were enriched for cytotoxic and immune surveillance populations, and DBA/2 J mice displayed elevated γδ T
Ella Trolio   +4 more
wiley   +1 more source

Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody. [PDF]

open access: yesAngew Chem Int Ed Engl, 2015
Martínez-Sáez N   +14 more
europepmc   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Study of the PD‐1 Inhibitor Cetrelimab in Chronic Hepatitis B

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 11, November 2026.
ABSTRACT Hepatitis B virus (HBV)‐induced T‐cell exhaustion may be reversed using a programmed death receptor 1 (PD‐1) inhibitor such as cetrelimab, an investigational fully human monoclonal antibody targeting PD‐1. To evaluate the safety, activity and pharmacokinetics of low‐dose (i.e., a dose lower than that used in oncology) cetrelimab in ...
Tarik Asselah   +10 more
wiley   +1 more source

Diagnostic Accuracy of Real Time Reverse Transcriptase Polymerase Chain Reaction for Chikungunya Virus Detection: A Systematic Review and Meta‐Analysis

open access: yesTropical Medicine &International Health, Volume 31, Issue 11, Page 1537-1547, November 2026.
ABSTRACT Background Chikungunya virus (CHIKV) is an arbovirus that causes an acute febrile illness with intense muscle and joint pain, with the possibility of progressing to a chronic or neurological stage. We conducted a systematic review and meta‐analysis with the aim of evaluating the accuracy of real‐time reverse transcriptase polymerase chain ...
Róger J. Costa   +8 more
wiley   +1 more source

Identification of a novel high‐prevalence red blood cell antigen on junctional adhesion molecule‐A defines a new blood group system

open access: yesVox Sanguinis, Volume 121, Issue 11, Page 1735-1743, November 2026.
Abstract Background and Objectives Availability of new technologies has accelerated the pace of blood group discovery, with nine of 48 known systems being discovered in the past 5 years alone, and yet uncharacterized antigens remain. This study involved investigations of samples from a female patient presenting with a moderate strength pan‐reactive ...
Tosti J. Mankelow   +7 more
wiley   +1 more source

Bioorthogonal Chemistry in Neurobiology: From Imaging to Proteomics

open access: yesChemBioChem, Volume 27, Issue 20, 28 October 2026.
This review highlights emerging strategies for labeling neuronal proteins, enabling visualization and quantitative analysis of their expression, localization, and dynamics. By combining genetic code expansion (GCE), metabolic labeling, and click chemistry‐based labeling, these approaches provide powerful routes to study proteins in specific cells and ...
Neil Taylor   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy